Promising data from Sangamo Therapeutics‘ research programs, including Alzheimer’s disease, were recently announced. The results were presented during the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C. Sangamo’s work in Alzheimer’s revealed a significant reduction in the production of tau, a…
New York-based Anavex Life Sciences presented data at the recent 13th International Conference on Alzheimer’s & Parkinson’s Diseases in Vienna showing that its compounds binding to the sigma-1 receptor hold promise in treating Alzheimer’s disease. Besides the well-known accumulation of amyloid beta peptide and the formation of senile plaques, researchers have extensively described the…
AXON Neuroscience announced that AADvac1, a vaccine against tau (a protein that accumulates and forms tangles inside neurons in diverse neurodegenerative diseases) showed therapeutic potential in Alzheimer’s disease (AD) and frontotemporal dementia (FTD) in a Phase 1 study. The announcement was made by Matej Ondrus, MD, the company’s medical director, at…
Sangamo Therapeutics‘ gene regulation technology significantly reduced levels of tau – a protein crucial to Alzheimer’s disease (AD) – in laboratory tissue experiments and a mouse model, the company announced. Sangamo’s collaborators from the Massachusetts General Hospital Alzheimer’s Disease Research Center and Harvard Medical School presented the results at the…
Reduced levels of the blood coagulation factor XII improves brain inflammation and cognitive deficits in Alzheimer’s disease, new research shows. The study, “Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer’s disease mice,” appeared in the journal Blood. Vascular (blood vessel) dysfunction and inflammation…
Caffeine, along with 23 other compounds, increases levels of a neuroprotective enzyme called NMNAT2 (nicotinamide mononucleotide adenylyl transferase 2), with potential implications for the treatment of dementia, new research shows. The study, “Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons,” appeared in…
Get regular updates to your inbox.